乳腺癌HER-2基因扩增与临床病理特征的相关性分析  

Fluorescence in situ hybridization on breast cancer HER-2 gene detection and its clinical pathological significance

作　　者：祝继原[1] 贾影[1] 方想[1] 孙悦[2] 梁超[1] 梁瑞[1] 戚基萍[1] 

机构地区：[1]哈尔滨医科大学附属第一医院病理科,黑龙江哈尔滨150001 [2]北京金菩嘉医疗科技有限公司,北京100083

出　　处：《哈尔滨医科大学学报》2013年第4期333-336,共4页Journal of Harbin Medical University

摘　　要：目的检测乳腺癌患者HER-2基因,并分析其与临床病理特征的相关性。方法采用荧光原位杂交方法(fluorescence in situ hybridization,FISH)检测328例乳腺癌石蜡标本的HER-2基因扩增状况,分析其与临床病理特征之间的关系。结果 328例乳腺癌患者HER-2基因,阳性率26.2%(86/328)。FISH与IHC结果的总符合率为72.0%。HER-2基因扩增状况与年龄差异不具有统计学意义(P>0.05),与肿瘤直径、病理类型、腋淋巴结转移数、临床分级的差异和HER-2受体蛋白表达的差异具有统计学意义(P<0.05)。结论 HER-2基因可作为判断乳腺癌预后及拟订治疗方案的良好指标。Objective To detect of HER-2 gene in patients with breast cancer, and analyze its clinical pathological significance. Methods Using fluorescence in situ hybridization （FISH） method for the detection of gene amplification status in 328 specimens of breast carcinomas, a- nalysis of gene amplification status and the relationship between clinic and pathological fea- tures. Results In 328 patients with HER-2 gene status in breast carcinoma, the positive rate was 26. 2% （86/328）. The total coincidence rate of FISH and IHC results was 72%. The am- plification of HER-2 gene had no significant relationship with the age, but with tumor size, pathological type, axillary lymph nodes metastasis expression number, differences in clinical classification and HER-2 gene expression, the differences were statistically significant （P 〈 0. 05）. Conclusion The HER-2 gene can be used as a good indicator to judge the prognosis of breast cancer and treatment options.

关 键 词：荧光原位杂交 HER-2基因扩增 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]